FDA Seeks Transparency in Data and Decisions - More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies. - BioPharm International

ADVERTISEMENT

FDA Seeks Transparency in Data and Decisions
More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.


BioPharm International
Volume 23, Issue 7

GUARDING SECRETS

An important consideration of the transparency initiative, said Sharfstein in a press briefing, is to obtain an "appropriate balance" between expanded disclosure and ensuring the confidentiality of trade secret information, which the task force acknowledges is key to maintaining investment in biomedical R&D. The panel says that a company's manufacturing methods and processes and its product formulations generally meet the trade secret definition and should remain private. But other data, such as clinical trial results and adverse event reports, may be more appropriate for disclosure. The task force wants to consider the public benefit withholding or releasing such information, as well as the often heavy cost of redacting trade secrets from to-be-disclosed material. Although the FDA is not proposing to release raw data from clinical trials, as opposed to summary information, the panel suggests that access to such information might be useful in some situations.

One factor guiding some FDA transparency proposals is the desire to harmonize US policies with those adopted by the European Medicines Agency (EMA). The Europeans already disclose when a company files a marketing application or withdraws one, as well as the agency's evaluation of the product. The EMA also posts its reasons for denying approval of a new product or additional indication, similar to the FDA's proposal for releasing CR letters.

Implementing many of the FDA transparency proposals will require legislative action, as well as new rulemaking. In unveiling these proposals, Sharfstein explained that the task force focused on what was the "right thing" to do, policy-wise, and did not evaluate the cost or feasibility of taking such action. Now the task force will review public comments on these proposals, which can be submitted through July 20, and conduct a legal and resource analysis for each item. Commissioner Hamburg will make the final decision on which proposals can be adopted internally and where it makes sense to seek Congressional action to permit more transparency in FDA decisions and documents.

Jill Wechsler is BioPharm International's Washington editor, Chevy Chase, MD, 301.656.4634,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here